Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2

PURPOSE: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. METHODS: In the phase III MONALEESA-2 study (NCT019580...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Sunil, O’Shaughnessy, Joyce, Burris, Howard A., Campone, Mario, Alba, Emilio, Chandiwana, David, Dalal, Anand A., Sutradhar, Santosh, Monaco, Mauricio, Janni, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022531/
https://www.ncbi.nlm.nih.gov/pubmed/29654415
http://dx.doi.org/10.1007/s10549-018-4769-z
_version_ 1783335698220187648
author Verma, Sunil
O’Shaughnessy, Joyce
Burris, Howard A.
Campone, Mario
Alba, Emilio
Chandiwana, David
Dalal, Anand A.
Sutradhar, Santosh
Monaco, Mauricio
Janni, Wolfgang
author_facet Verma, Sunil
O’Shaughnessy, Joyce
Burris, Howard A.
Campone, Mario
Alba, Emilio
Chandiwana, David
Dalal, Anand A.
Sutradhar, Santosh
Monaco, Mauricio
Janni, Wolfgang
author_sort Verma, Sunil
collection PubMed
description PURPOSE: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. METHODS: In the phase III MONALEESA-2 study (NCT01958021), 668 patients were randomized 1:1 to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. PROs were assessed using the European Organisation for Research and Treatment of Cancer core quality-of-life (EORTC QLQ-C30) and breast cancer-specific (EORTC QLQ-BR23) questionnaires. Changes from baseline and time to deterioration in health-related quality of life (HRQoL) were analyzed using linear mixed-effect and stratified Cox regression models, respectively. Exploratory analysis of area-under-the-curve for change from baseline in pain score (AUC-pain) was performed. RESULTS: On-treatment HRQoL scores were consistently maintained from baseline and were similar between arms. A clinically meaningful (> 5 points) reduction in pain score was observed as early as Week 8 and was maintained up to Cycle 15 in the ribociclib arm. A statistically significant increase in mean AUC-pain was also observed in the ribociclib arm. Scores for all other EORTC QLQ-C30 and EORTC QLQ-BR23 domains were maintained from baseline and were similar between arms. CONCLUSIONS: HRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2− advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population.
format Online
Article
Text
id pubmed-6022531
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-60225312018-07-06 Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2 Verma, Sunil O’Shaughnessy, Joyce Burris, Howard A. Campone, Mario Alba, Emilio Chandiwana, David Dalal, Anand A. Sutradhar, Santosh Monaco, Mauricio Janni, Wolfgang Breast Cancer Res Treat Clinical Trial PURPOSE: Evaluate patient-reported outcomes (PROs) for postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer treated with first-line ribociclib plus letrozole. METHODS: In the phase III MONALEESA-2 study (NCT01958021), 668 patients were randomized 1:1 to ribociclib (600 mg/day; 3-weeks-on/1-week-off) plus letrozole (2.5 mg/day) or placebo plus letrozole. PROs were assessed using the European Organisation for Research and Treatment of Cancer core quality-of-life (EORTC QLQ-C30) and breast cancer-specific (EORTC QLQ-BR23) questionnaires. Changes from baseline and time to deterioration in health-related quality of life (HRQoL) were analyzed using linear mixed-effect and stratified Cox regression models, respectively. Exploratory analysis of area-under-the-curve for change from baseline in pain score (AUC-pain) was performed. RESULTS: On-treatment HRQoL scores were consistently maintained from baseline and were similar between arms. A clinically meaningful (> 5 points) reduction in pain score was observed as early as Week 8 and was maintained up to Cycle 15 in the ribociclib arm. A statistically significant increase in mean AUC-pain was also observed in the ribociclib arm. Scores for all other EORTC QLQ-C30 and EORTC QLQ-BR23 domains were maintained from baseline and were similar between arms. CONCLUSIONS: HRQoL was consistently maintained from baseline in postmenopausal women with HR+, HER2− advanced breast cancer receiving ribociclib plus letrozole and was similar to that observed in the placebo plus letrozole arm. Together with the improved clinical efficacy and manageable safety profile, these PRO results provide additional support for the benefit of ribociclib plus letrozole in this patient population. Springer US 2018-04-13 2018 /pmc/articles/PMC6022531/ /pubmed/29654415 http://dx.doi.org/10.1007/s10549-018-4769-z Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Trial
Verma, Sunil
O’Shaughnessy, Joyce
Burris, Howard A.
Campone, Mario
Alba, Emilio
Chandiwana, David
Dalal, Anand A.
Sutradhar, Santosh
Monaco, Mauricio
Janni, Wolfgang
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
title Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
title_full Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
title_fullStr Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
title_full_unstemmed Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
title_short Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2
title_sort health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from monaleesa-2
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022531/
https://www.ncbi.nlm.nih.gov/pubmed/29654415
http://dx.doi.org/10.1007/s10549-018-4769-z
work_keys_str_mv AT vermasunil healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT oshaughnessyjoyce healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT burrishowarda healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT camponemario healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT albaemilio healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT chandiwanadavid healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT dalalananda healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT sutradharsantosh healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT monacomauricio healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2
AT janniwolfgang healthrelatedqualityoflifeofpostmenopausalwomenwithhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancertreatedwithribociclibletrozoleresultsfrommonaleesa2